Cosmos Health Inc. reported first-quarter 2026 results with revenue rising 30.7% year over year to $17.93M while the company recorded a loss attributable to common stockholders and wider EPS compared with the prior-year quarter.

Financial Highlights

Metric	Current quarter	Prior year quarter	YoY change
Revenue¹	$17.93M	$13.71M	30.7%
Net income²	($2.81M)	($818.1K)	(242.9%)
Diluted EPS³	($0.06)	($0.03)	(100%)

¹ Reported as “Revenue”. ² Reported as “Net Loss Attributable To Common Stockholders”. ³ Reported as “Loss Per Share”.

Business Highlights

Revenue growth was driven by subsidiaries SkyPharm, Cosmofarm and Cana, with an overall shift in mix toward wholesale distribution (Cosmofarm) that lowered gross margins.
Sky Premium Life® expanded into the UAE, Cyprus and Greece, with major purchase orders expected in 2026.
Cana increased contract manufacturing activity; Cosmofarm added roughly 75 pharmacies and invested in robotics and automation to support distribution scale-up.
Strategic initiatives include ongoing M&A activity, the Cloudscreen AI acquisition, and international distribution deals to scale products and the R&D pipeline.

Original SEC Filing: Cosmos Health Inc. [ COSM ] - 10-Q - May. 20, 2026

Disclaimer

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Cosmos Health Inc. 1Q 2026: Revenue $17.93M, EPS ($0.06) — 10-Q Summary